Shares of Artivion (AORT) tumbled 6.64% in after-hours trading on Monday, following the company's disappointing fourth quarter 2024 earnings report. The medical device maker missed Wall Street's expectations on both the top and bottom lines.
For the quarter, Artivion reported adjusted earnings per share of $0, falling short of analysts' consensus estimate of $0.06 per share. The company also fell short on revenue, generating $97.31 million compared to the $100.82 million projected by analysts.
The weaker-than-expected results weighed on investor sentiment, with Artivion's stock shedding over 6% of its value in extended trading hours after the earnings miss. Investors appeared disappointed by the company's lackluster performance to close out fiscal 2024.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
If the download button clicks without skipping, click on the top right menu and select "Open in Browser."